Notizie e Video - NEOVACS - Inglese

Attualmente stai visualizzando tutte le notizie di borsa dello strumento finanziario NEOVACS in tutti i mercati in Inglese.

> Notizie28/12/2022 - 14:20 ACCESSWIRE ha pubblicato una nuova notizia.

Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Development 28/12/2022 - 14:20• • ACCESSWIRE • Azioni

Increase in the funding commitment of Néovacs to cover cash requirements through the topline results of the pivotal Phase III clinical study of the drug candidate PXT3003, the PREMIER trial, in development in Charcot-Marie-Tooth Disease Type1A (CMT1A) Appointment of Hugo Brugière as Chairman and CEO Creation of an ad hoc committee dedicated to the search for a strategic industrial partner to develop the Company's assets and potential PARIS, FRANCE / ACCESSWIRE / December 28, 2022 / Pharnext SA...

Grazie Grafico

> Notizie19/05/2020 - 15:30 Actusnews ha pubblicato una nuova notizia.

NEOVACS SHARES TO RESUME TRADING ON MAY 20TH, 2020 19/05/2020 - 15:30• • Actusnews • Azioni

Paris and Boston, May 19 th , 2020 5:30 PM CET - Néovacs (Euronext Growth Paris: ALNEV) confirms that it has requested the resumption of trading in its shares on Euronext as soon as possible in accordance with the commitment made in its press release dated May 18 th , 2020 [1] . The resumption of trading follows on from the Paris Commercial Court's approval of the draft continuity plan presented by HBR Investment Group. The approval of the plan will enable Néovacs to close ongoing receivership...

Grazie Grafico

> Notizie18/05/2020 - 05:00 Actusnews ha pubblicato una nuova notizia.

VALIDATION OF THE "RESTARTED" PLAN BY THE PARIS COMMERCIAL COURT 18/05/2020 - 05:00• • Actusnews • Azioni

End of court-ordered receivership proceedings Continuation of core research in lupus and allergies Creation of a new business investing in BioTechs and MedTechs New shareholder (HBR Investment Group) and changes in governance Restructuring of liabilities Transfer of ORNANE financing agreement of a total residual nominal amount of €5.85 million over a maximum period of 10 months, in favor of HBR Investment Group, and signing of a new OCEANE-BSA financing agreement for a maximum nominal amount...

Grazie Grafico

> Notizie04/05/2020 - 16:30 Actusnews ha pubblicato una nuova notizia.

DRAFT CONTINUITY PLAN // REVIEW HEARING SCHEDULED FOR MAY 6th, 2020 04/05/2020 - 16:30• • Actusnews • Azioni

Paris and Boston, May 4 th , 2020 – 18.00 CET - Néovacs (Euronext Growth Paris: ALNEV) today provides an update on the ongoing insolvency proceedings. The Paris Commercial Court will review the sole Néovacs draft continuity plan presented and submitted by HBR Investment Group, during a video-conference hearing scheduled for May 6 th , 2020 at 2.00 pm. The continuity plan primarily includes: Acquisition of an equity interest in Néovacs by HBR Investment Group as part of the continuity plan;...

Grazie Grafico

> Notizie09/03/2020 - 17:30 Actusnews ha pubblicato una nuova notizia.

EXTENSION OF THE OBSERVATION PERIOD IN THE FRAME OF REOGANIZATION PROCEEDINGS AND UPDATE ON RandD PROGRAMS 09/03/2020 - 17:30• • Actusnews • Azioni

Paris and Boston, March 9 th , 2020 – 6h30 pm CET - Neovacs (Euronext Growth Paris: ALNEV) announces that it has obtained a 6-month extension of its observation period and reports an update on the two research programs. REOGANIZATION PROCEEDINGS On November 26th, 2019 the Commercial Court of Paris decided the opening of reorganization proceedings of the company with an observation period initially set for 3 months. At the end of this period and after a hearing before the Tribunal held in the...

Grazie Grafico

> Notizie06/12/2019 - 16:45 GlobeNewsWire ha pubblicato una nuova notizia.

OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS 06/12/2019 - 16:45• • GlobeNewsWire • Azioni

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE OPENING OF A CALL FOR TENDER TO PROVIDE A CONTINUATION OR SALE PLAN IN THE FRAME OF REOGANIZATION PROCEEDINGS The deadline for submission of all tenders is January 10 th , 2020 before 04:00pm Paris and Boston, December 6 th , 2019 – 05h45pm CET - Neovacs (Euronext Growth Paris : ALNEV) announces the launch of a call for tender opened from now until January 10 th , 2020 before 4:00 pm, to provide a continuation plan through...

Grazie Grafico

> Notizie02/10/2019 - 19:31 GlobeNewsWire ha pubblicato una nuova notizia.

NEOVACS ANNOUNCES ITS 2019 HALF-YEAR RESULTS 02/10/2019 - 19:31• • GlobeNewsWire • Azioni

PRESS RELEASE PRESS RELEASE · PRESS RELEASE · PRESS RELEASE PRESS RELEASE NEOVACS ANNOUNCES ITS 2019 HALF-YEAR RESULTS Paris and Boston, 2 nd October, 2019— 9:30 p.m. CEST—NEOVACS (Euronext Paris: ALNEV, eligible for PEA-PME), a leading provider of therapeutic vaccines for the treatment of autoimmune diseases, announced today its 2019 half-year results for the period ending on 30 th June 2019, approved by the Board of Directors on 2 nd October 2019. Results for the first half of 2019: Cash...

Grazie Grafico

> Notizie30/09/2019 - 06:30 GlobeNewsWire ha pubblicato una nuova notizia.

NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER 30/09/2019 - 06:30• • GlobeNewsWire • Azioni

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES APPOINTMENT OF VINCENT SERRA AS CHIEF EXECUTIVE OFFICER Paris & Boston, September 30, 2019 – 08h30am CEST - Neovacs (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of auto-immune diseases, has today announced, the appointment of Vincent Serra, PhD, as the new Chief Executive Officer, with immediate effect, to succeed Miguel Sieler who has resigned as CEO and as a board director. Jean-Jacques...

Grazie Grafico

> Notizie09/09/2019 - 15:45 GlobeNewsWire ha pubblicato una nuova notizia.

Neovacs : 2019 Financial Calendar 09/09/2019 - 15:45• • GlobeNewsWire • Azioni

PRESS RELEASE PRESS RELEASE PRESS RELEASE 2019 Financial Calendar Paris, September 9, 2019, 5:45 pm CEST – NEOVACS (Euronext Growth Paris: ALNEV) leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases publishes an updated 2019 financial calendar today. Financial announcements will be published before the market opening. The expected dates are preliminary so may be subject to change. 2019 First Half Results October 2, 2019 2019 Annual Results March 29, 2020...

Grazie Grafico

> Notizie09/07/2019 - 05:30 GlobeNewsWire ha pubblicato una nuova notizia.

NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT 09/07/2019 - 05:30• • GlobeNewsWire • Azioni

· PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THAT THE POSITIVE RESULTS OF ITS PROOF OF CONCEPT IN ALLERGIES WITH IL-4 / IL-13 KINOID HAVE TRIGGERED THE FIRST PAYMENT OF THE ANR GRANT Paris and Boston, July 9, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, has today announced having received a first payment within the grant awarded by the National Agency for Research (ANR)...

Grazie Grafico

> Notizie27/06/2019 - 05:30 GlobeNewsWire ha pubblicato una nuova notizia.

NEOVACS ANNOUNCES THE APPOINTMENT of Dr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR 27/06/2019 - 05:30• • GlobeNewsWire • Azioni

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS ANNOUNCES THE APPOINTMENT of Dr. VIRGINIA PASCUAL AS MEDICAL AND SCIENTIFIC ADVISOR Paris and Boston, June 27 th , 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announces the appointment of Dr. Virginia Pascual as Medical and Scientific advisor . “ We are delighted to welcome Dr Pascual to Neovacs. Her significant contribution to lupus...

Grazie Grafico

> Notizie05/06/2019 - 05:30 GlobeNewsWire ha pubblicato una nuova notizia.

Neovacs to present the pre-clinical results of its IFNalpha Kinoid to treat type 1 diabetes - American Diabetes Association's 79th scientific sessions 05/06/2019 - 05:30• • GlobeNewsWire • Azioni

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT THE PRE-CLINICAL RESULTS OF ITS IFNα KINOID TO TREAT TYPE 1 DIABETES AT T HE AMERICAN DIABETES ASSOCIATION'S 79TH SCIENTIFIC SESSIONS (ADA) “IFNα Kinoid: A promising vaccine against Type 1 Diabetes Targeting IFN-alpha in NOD Mice” San Francisco, CA, USA - June 7- 11, 2019 Paris and Boston, June 5, 2019 – Neovacs – 7:30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of...

Grazie Grafico

> Notizie16/05/2019 - 05:30 GlobeNewsWire ha pubblicato una nuova notizia.

Neovacs to present the pre-clinical results of its therapeutic vaccine candidate IL-4 / IL-13 Kinoid to treat allergic Asthma 16/05/2019 - 05:30• • GlobeNewsWire • Azioni

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT THE PRE-CLINICAL RESULTS OF ITS THERAPEUTIC VACCINE CANDIDATE IL-4 / IL-13 KINOID TO TREAT ALLERGIC ASTHMA « Antibodies and Complement 2019 » - Girona, Spain- May 20-25, 2019 « EAACI 2019 » - Lisbon, Portugal, June 1-5 2019 Paris and Boston, May 16, 2019 – Neovacs - 07h30 am CEST - (Euronext Growth Paris : ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the presentation...

Grazie Grafico

> Notizie25/03/2019 - 06:30 GlobeNewsWire ha pubblicato una nuova notizia.

Neovacs reports full-year 2018 Financial results and provides corporate update 25/03/2019 - 06:30• • GlobeNewsWire • Azioni

RESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS REPORTS FULL-YEAR 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE KEY OPINION LEADERS VALIDATE THE THERAPEUTIC POTENTIAL OF IFNα KINOID IN LUPUS TREATMENT FOLLOWING THE RESULTS OF THE PHASE IIB CLINICAL STUDY SUCCESSFUL IN VIVO PROOF OF CONCEPT FOR ITS IL-4 / IL-13 KINOID A NEW THERAPEUTIC VACCINE TO TREAT MITE-INDUCED ASTHMA PATENT REGISTERED IN EUROPE AND THE U.S. FOR IL-4 / IL-13 KINOID, CANDIDATE VACCINE IN THE TREATMENT OF...

Grazie Grafico

> Notizie19/02/2019 - 12:30 GlobeNewsWire ha pubblicato una nuova notizia.

Néovacs : Agenda financier 2019 19/02/2019 - 12:30• • GlobeNewsWire • Azioni

COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE · COMMUNIQUE DE PRESSE AGENDA FINANCIER 2019 Paris et Boston, le 19 février 2019 – NÉOVACS (Euronext Growth Paris : ALNEV), leader de l’immunothérapie active pour le traitement des maladies auto-immunes, présente aujourd’hui son agenda financier 2019. Les publications financières auront lieu avant ouverture du marché. Ce calendrier est indicatif et peut être soumis à modifications. Résultats annuels 2018 mardi 16 avril 2019 Assemblée...

Grazie Grafico

> Notizie05/02/2019 - 01:30 GlobeNewsWire ha pubblicato una nuova notizia.

Neovacs to host KOL Meeting to discuss its therapeutic vaccin IFNalpha Kinoid for lupus treatment - February 11th Paris 05/02/2019 - 01:30• • GlobeNewsWire • Azioni

NEOVACS TO HOST KOL MEETING TO DISCUSS ITS THERAPEUTIC VACCINE IFN α KINOID FOR LUPUS TREATMENT FEBRUARY 11, 2019 – 17h00 Hôtel Renaissance Le Parc Trocadéro – Paris Paris and Boston, February 5 th 2019 – 7h30 CET - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases announces an event with Key Opinion Leaders specializing in auto-immune diseases and rheumatology to discuss its ground breaking product, the...

Grazie Grafico

> Notizie24/01/2019 - 11:45 GlobeNewsWire ha pubblicato una nuova notizia.

Neovacs to present full results from the Phase IIb IFNalpha Kinoid clinical study at the 13th International Lupus Congress 24/01/2019 - 11:45• • GlobeNewsWire • Azioni

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS TO PRESENT FULL RESULTS FROM THE PHASE IIb IFNalpha KINOID CLINICAL STUDY AT THE 13 TH INTERNATIONAL LUPUS CONGRESS (LUPUS 2019) 5 - 9 APRIL, SAN FRANCISCO Paris & Boston, January 24 th , 2019 – 17:45 pm CET - Neovacs (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune and inflammatory diseases announces that it has been selected to present the results of its Phase IIb IFNα Kinoid clinical...

Grazie Grafico

> Notizie08/01/2019 - 06:30 GlobeNewsWire Europe ha pubblicato una nuova notizia.

NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT 08/01/2019 - 06:30• • GlobeNewsWire Europe • Azioni

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE NEOVACS SECURES FINANCING FROM THE ANR - THE FRENCH NATIONAL RESEARCH AGENCY - TO DEVELOP THE IL-4/IL-13 KINOID AS AN ALLERGY TREATMENT Paris and Boston, January 8, 2019 - 7:30 CET - Neovacs (Euronext Paris Growth Paris: ALNEV), leader in active immunotherapy for the treatment of auto-immune diseases, announces that its AllergyVACS project has been selected to receive funding from the French National Research Agency (ANR) following the latter's...

Grazie Grafico

> Notizie11/12/2018 - 06:30 GlobeNewsWire Europe ha pubblicato una nuova notizia.

Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid 11/12/2018 - 06:30• • GlobeNewsWire Europe • Azioni

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs and Centurion Pharma continue their collaboration in Lupus based on the results of the Phase IIb trial with IFNalpha Kinoid Paris and Boston, December 11 th 2018 - 7:30 am CET - Neovacs (Euronext Growth Paris: ALNEV ), leader in the field of active immune therapy for the treatment of autoimmune-diseases, confirms the decision of Centurion Pharma to pursue the partnership on the basis of the licensing agreement signed between both companies...

Grazie Grafico

> Notizie20/11/2018 - 16:45 GlobeNewsWire Europe ha pubblicato una nuova notizia.

Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/IL-13 for the treatment of allergies 20/11/2018 - 16:45• • GlobeNewsWire Europe • Azioni

PRESS RELEASE · PRESS RELEASE · PRESS RELEASE Neovacs announces the patent filing in Europe and in the United States for its new therapeutic vaccine candidate Kinoid IL-4/IL-13 for the treatment of allergies Paris and Boston, November 20 th 2018 - 17h45 CET (Euronext Growth Paris: ALNEV), leader in active immunotherapy for the treatment of autoimmune and inflammatory diseases, announces patent filing after having achieved preclinical proof of concept with its new vaccine IL-4/IL-13 Kinoid for...

Grazie Grafico